CTS (CTS) Proxy filing summary

Executive summary

• Achieved $541 million in 2025 revenue, up 5% from 2024, with strong growth in medical, industrial, and aerospace & defense markets, offsetting a 7% decline in transportation sales.

• Generated $102 million in operating cash flow and returned $62 million to shareholders via dividends and share repurchases.

• Launched Evolution 2030 strategy focused on Growth, Operational Excellence, and Engagement.

• Annual meeting scheduled for May 14, 2026, with proxy materials available online.

Voting matters and shareholder proposals

• Shareholders to vote on: election of eight directors for one-year terms, advisory approval of executive compensation, and ratification of Grant Thornton LLP as independent auditor for 2026.

• Board recommends voting FOR all proposals.

Board of directors and corporate governance

• Board consists of eight directors, all independent except the Chair; diverse in skills and backgrounds.

• Annual election of directors, majority voting standard, and director resignation policy in place.

• Four standing committees: Audit, Compensation and Talent, Nominating, Governance and Sustainability, and Technology and Transactions.

• Lead Independent Director role provides additional oversight and shareholder engagement.

• Stock ownership guidelines for executives and directors to align interests with shareholders.